Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Kyowa Kirin Limited, Galabank Business Park, Galashiels, TD1 1QH, United Kingdom
Moxisylyte is an alpha-adrenergic blocking agent. Opilon tablets are indicated in the short term control of the symptoms of primary Raynaud’s phenomenon.
Oral administration.
Initially one tablet to be taken four times a day. This may be increased to two tablets four times a day if initial response is poor. For patients exposed to the cold during the daytime, one tablet should be administered every three hours during the period when symptoms are most likely to occur. In the event that a response is not evident within 2 weeks, the drug should be discontinued.
As for adults.
No clinical or pharmacokinetic data specific to this age group are available. Whilst at normal dosage no problems have been reported, caution nevertheless is advised when Opilon tablets are prescribed in the elderly.
Opilon tablets are not indicated for use in children.
In excessive overdosage a fall in blood pressure is the main symptom. The patient should be nursed in the supine position until the blood pressure has been restored to normal.
36 months.
Store at a temperature not exceeding 30°C.
Blister pack comprising white PVC and aluminium foil backing containing 112 tablets.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
